Vivo Capital in equity financing of Harmony Biosciences, LLC

DLA Piper represented healthcare-focused investment firm Vivo Capital as the lead investor in a US$270 million equity financing of Harmony Biosciences, LLC, a biopharmaceutical company that develops orphan and rare disease therapies.

Harmony used the funds to acquire exclusive US rights from French company Bioprojet SCR for the development and distribution of the drug pitolisant, a selective histamine H3-receptor antagonist/inverse agonist used to treat narcolepsy.

The DLA Piper team representing Vivo Capital consisted of partners Louis Lehot, Shane Albright, Cisco Palao-Ricketts (all of Silicon Valley); Lisa Haile (San Diego); Thomas deButts (Washington, DC); and Paolo Morante (New York); associates Spencer Markel, Jaspreet Mann (both of San Francisco); and SeoJung Park (Silicon Valley); and Malaz Kamal Moustafa (Silicon Valley).

DLA Piper's global life sciences lawyers work across practice areas and offices to support biotechnology and medical device clients at every stage of growth, from startups to fast-growing and mid-market businesses to mature global enterprises. Last year, according to Mergermarket's league tables for legal advisors, DLA Piper again earned the top ranking globally for overall deal volume and ranked first for technology M&A in the US. DLA Piper was highly ranked in other notable league tables for 2016, including placing in the top five of each M&A, venture capital and private equity category recognized by PitchBook – the only law firm to do so.

DLA Piper